 Annexon Inc NASDAQ: ANNX shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntingtons disease, which causes a progressive breakdown of nerve cells in the brain. The 28 patients were dosed for six months and followed for three more. 